The British government is poised to increase its expenditure on medicines for the National Health Service, the Financial Times reported. This move is intended to address a major gripe voiced by U.S. President Donald Trump, who has implemented steep tariff hikes on branded medications.

Without confirming the details, a UK government spokesperson stated there is a ongoing 'constructive dialogue' with both the U.S. and the pharmaceutical industry. The aim is to support the sector's innovation while ensuring value for taxpayers, they added.

Meanwhile, British pharmaceutical giants like AstraZeneca and GlaxoSmithKline continue to establish manufacturing facilities in the U.S., aligning with Trump's call for lowered drug prices or the threat of a hefty new tariff.

See Full Page